China's BCI Race Heats Up as BrainCo and Neuracle Eye IPOs, Funding Jumps 230%
China's two leading brain-computer interface firms are simultaneously sprinting toward public listings, as sector financing in the first half of 2026 surpassed RMB 4 billion (US$556 million) — already exceeding full-year 2025 totals and up 230% year-on-year — signaling that the country's BCI industry has crossed from laboratory curiosity into investable asset class.
The dual IPO push crystallized on June 9, when CITIC Securities filed a completed IPO guidance report with China's securities regulator on behalf of Neuracle Technology, indicating the Shanghai-based firm finished its mandatory pre-listing coaching process on May 6 — just three months after submitting its guidance registration in early February. The company is targeting a listing on the STAR Market. Meanwhile, BrainCo, one of the so-called "Hangzhou Six Dragons," had already moved in late January, filing a confidential IPO application with the Hong Kong Stock Exchange. No disclosure has been made public as of press time.
The race for what the market has dubbed the "first BCI stock" is more than a branding contest. Whichever firm crosses the finish line first will set valuation benchmarks, unlock secondary-market liquidity for a sector that has operated almost entirely on private capital, and potentially catalyze a wave of follow-on listings from a crowded field of clinical-stage competitors.
Neuracle Secures Regulatory Moat, Clearing Path to STAR Market
Neuracle's IPO ambitions rest on a regulatory milestone that no competitor globally has yet matched. In March 2026, the company's implantable neural interface system received a Class III medical device registration certificate from China's National Medical Products Administration (NMPA), making it the world's first invasive BCI medical device to obtain commercial approval anywhere.
The product — formally designated the "Implantable Brain-Computer Interface Hand Motor Function Compensation System" — operates as a semi-invasive architecture distinct from Neuralink's fully penetrating electrode approach. Neuracle's electrodes are positioned on the dura mater between the skull and cerebral cortex, enabling wireless power delivery from an external unit and minimizing neuronal damage. The design trade-off sacrifices some signal resolution for substantially lower surgical risk, a calculus that resonates with both regulators and hospital procurement committees.
Clinical data underpinning the approval is compelling. By December 2025, 32 patients with cervical spinal cord injuries had undergone NEO implantation across 11 hospitals nationwide, including Beijing Tiantan Hospital, Shanghai Huashan Hospital, and Jiangsu Provincial People's Hospital. The company disclosed a 100% primary endpoint achievement rate across all enrolled patients, with subjects regaining home-based brain-controlled grasping and rehabilitation training capability.
The commercial pathway accelerated further when Shanghai's municipal healthcare insurance bureau fast-tracked the device into its medical consumables reimbursement catalog in late March — within one week of NMPA approval — completing the clinical-billing-reimbursement loop that most medtech startups spend years trying to close. This insurance inclusion is a structural advantage that will be difficult for rivals to replicate quickly and materially de-risks Neuracle's near-term revenue ramp.
Founded in 2011 by researchers from Tsinghua University's Neural Engineering Laboratory — consistently ranked among the world's top BCI research centers — Neuracle has accumulated 17 technical patents and nine software copyrights. Its post-money valuation following an unconfirmed D+ round in 2025 is estimated at RMB 3.5–4 billion (US$486–556 million).
BrainCo Bets on Scale and Embodied AI Premium to Command Higher Valuation
BrainCo's strategic positioning diverges sharply from Neuracle's invasive-medical focus. Founded in 2015, the Hangzhou-based firm has built its franchise around non-invasive BCI applications — sidestepping the surgical risk that historically constrained consumer adoption — and has parlayed that into a RMB 8.8 billion (US$1.22 billion) estimated valuation, more than double Neuracle's.
The valuation gap is driven partly by BrainCo's January 2026 financing round of RMB 2 billion (US$278 million), which broke the domestic BCI funding record and ranked as the second-largest single BCI raise globally after Neuralink. The round reflects investor conviction in BrainCo's dual-track model: medical-grade applications targeting sleep improvement, stress reduction, and ADHD attention training on one side, and a rapidly scaling intelligent prosthetics business on the other.
The prosthetics arm carries particular valuation weight. BrainCo claims to have shipped the world's first mass-produced intuition-controlled bionic hand in 2025, a device that has received FDA clearance and can execute force-differentiated grasping — crushing an egg with maximum grip, then switching to recover a fragile eggshell fragment — without manual intervention. The system captures electromyographic and neural signals to enable five-finger coordinated operation, restoring fine motor capability to upper-limb amputees.
This positions BrainCo squarely within the embodied intelligence investment narrative that has commanded premium multiples across Chinese tech in 2026. The company has stated ambitions to serve 10 million patients suffering from autism, ADHD, Alzheimer's disease, and insomnia, and to equip one million physically disabled individuals with neural-controlled prosthetics within five to ten years.
Critically for its Hong Kong IPO story, BrainCo has achieved scaled commercial revenue — a distinction that sets it apart from the majority of domestic BCI peers still in clinical-stage development.
Funding Frenzy Reflects Policy Tailwinds Reshaping the Investment Landscape
The IPO race is unfolding against a financing backdrop that has fundamentally repriced the sector's risk profile. In full-year 2025, Chinese BCI companies completed 26 funding rounds totaling RMB 1.778 billion (US$247 million), a dramatic increase from just seven funding rounds and RMB 230 million (US$31.9 million) in 2024. In the first half of 2026 alone, 34 rounds have closed, with disclosed amounts already exceeding RMB 4 billion (US$556 million), a 230% year-on-year acceleration that has made the full-year 2025 total look modest.
The capital surge is not occurring in a policy vacuum. Several developments in 2026 have materially improved the sector's regulatory and investment outlook.
A foundational step came on January 1, when China's first brain-computer interface medical device terminology standard took effect. The framework established a common regulatory language for device evaluation and approval, reducing a layer of uncertainty that had long complicated both product development and investment decisions.
Momentum accelerated further in March, when brain-computer interfaces were written into the Government Work Report at the Fourth Session of the 14th National People's Congress. Alongside quantum technology and embodied intelligence, BCI was identified as a priority future industry, signaling sustained policy support at the highest level.
The national endorsement has since been followed by local implementation. Provincial-level action plans have emerged across Jiangsu, Guangdong, Hainan, Beijing, Tianjin, and Sichuan, translating strategic priorities into measurable industry targets. Jiangsu's plan, released jointly by nine government departments in March, aims to secure medical device approvals for at least 20 BCI products by 2030, cultivate two to three nationally influential companies, and build a standardized dataset containing more than 20,000 trial and patient samples.
Clinical Pipeline Signals China Is Closing the Gap With Global Leaders
Beyond the two IPO candidates, the broader domestic pipeline is generating clinical data that challenges the assumption of Chinese technological subordination in this field.
On June 8, a team led by Wenzhou researcher Yang Jiawei, in collaboration with NurotechMed, reported the successful completion of China's first high-resolution visual BCI clinical trial. The patient was able to identify letters on the second day post-implant activation, with projected visual acuity recovery to 0.5 — a significant advance in visual reconstruction, the second-largest clinical application domain for BCI.
BeiNao-1, a domestically developed semi-invasive BCI system, has completed 16 implantations across 16 research centers as of late May 2026, with the longest implant duration exceeding one year and cumulative safe operating time surpassing 55,000 hours. The program targets 40 total implants by year-end and plans to initiate BeiNao-2 clinical validation in H2 2026, with a nationwide rollout to qualified tertiary hospitals slated for 2027.
Jietai Medical completed a clinical implant of its 256-channel wireless high-throughput invasive BCI system (WRS02) in early 2026 using its proprietary surgical robot, and plans to launch a large-scale multi-center registration trial targeting approximately 40 patient enrollments this year — a volume that would put its cumulative implant count in range of Neuralink's. Zhiran Medical in May initiated China's first prospective, multi-center clinical trial for a fully implanted BCI system with over 100 channels, enrolling 32 patients across 11 hospitals.
Impact Assessment: What the "First BCI Stock" Milestone Means for Investors
The listing of either Neuracle or BrainCo will serve as a price discovery event for an asset class that has until now been valued entirely through private-market negotiations. For venture and growth-stage investors holding positions in the 30-plus companies that have received funding in 2026, a public comparable will either validate or reset portfolio marks.
More structurally, the first listing will test whether China's public markets are prepared to value pre-profitability deep-tech medtech companies on a forward clinical and regulatory pipeline basis — the framework that has driven valuations for comparable firms on NASDAQ. The STAR Market's science-and-technology orientation makes it the more natural venue for this test, but BrainCo's Hong Kong route, with its access to international institutional capital, could produce a higher absolute valuation if the company's revenue traction is sufficient to anchor a growth multiple.
The competitive asymmetry between the two firms is instructive: Neuracle holds the regulatory first-mover advantage and insurance reimbursement inclusion that generate near-term, defensible revenue; BrainCo holds a higher valuation, broader product portfolio, and a consumer-facing narrative that travels more easily across investor geographies. Neither advantage is permanent, and the IPO process itself will force both companies to disclose financials that the market has not yet seen.
Related Coverage:
China Greenlights World’s First Invasive Brain-Computer Interface for Commercial Clinical Use